Liposomal NDDP(Liposomal NDDP) - 药物靶点：DNA_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Aroplatin、L-NDDP、NDDP

+ [5]

靶点

DNA

作用机制

DNA抑制剂(DNA抑制剂)、DNA烷化剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [3]

在研适应症-

非在研适应症

晚期结直肠腺癌晚期恶性实体瘤B细胞淋巴瘤+ [10]

原研机构

The University of Texas MD Anderson Cancer Center

在研机构-

非在研机构

Aronex Pharmaceuticals, Inc.

Agenus, Inc.

The University of Texas MD Anderson Cancer Center

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C26H52N2O4Pt

InChIKeyPZAQDVNYNJBUTM-UHFFFAOYSA-L

CAS号113427-19-3

关联

5

项与 Liposomal NDDP 相关的临床试验

NCT00081536 / Unknown status临床1/2期

A Phase I/II Study of Aroplatin and Capecitabine in Subjects With Unresectable Local Recurrence or Distant Metastases of Colorectal Cancer Refractory to 5-FU/Leucovorin and Irinotecan

This study is a Phase I/II study. In Phase I of this study, the objective is to determine the maximum tolerated dose (MTD) of combination therapy with Aroplatin and capecitabine in subjects with unresectable, local recurrence or distant metastases of colorectal cancer refractory to 5-FU/leucovorin and irinotecan. In Phase II, the primary objective is to evaluate the response proportion and duration with Aroplatin/capecitabine therapy. Secondary objectives are to evaluate frequency and severity of adverse events.

开始日期-

申办/合作机构

Aronex Pharmaceuticals, Inc.

NCT00316511 / Completed临床1期

A Phase 1 Multi-Center, Dose Escalation and Pharmacokinetic Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma

This is a dose escalation study. Patients will be enrolled in cohorts of three patients each, and escalation of dose to the next cohort will be determined based on dose-limiting toxicity (DLT) in the previous cohort. This study aims to identify the maximum tolerated dose (MTD) of intravenous L-NDDP. Once the MTD has been determined, an additional four patients will be enrolled at that dose level. While the MTD is determined based on safety data from each cohort's first cycle of L-NDDP therapy only, patients may continue treatment with additional cycles of L-NDDP at the same dose as their starting dose until documented progression, unacceptable toxicity, or another off study criterion is met. Patients who have not met any of the off study criteria and continue to receive L-NDDP therapy at the time when MTD is determined may be allowed to change L-NDDP dose to the MTD dose level. The study will also determine the pharmacokinetic profile of L-NDDP administration. Clinical activity of L-NDDP in solid tumor patients will be assessed as tumor response using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Clinical activity of L-NDDP in B-cell lymphoma patients will be assessed using the International Working Group recommendations.

开始日期2006-03-01

申办/合作机构

Agenus, Inc.

NCT00004033 / Completed临床2期IIT

Phase II Clinical Study of a Liposome Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally in Patients With Malignant Pleural Mesothelioma

RATIONALE: Patient abstract not available
PURPOSE: Patient abstract not available

开始日期1998-09-01

申办/合作机构

NYU Langone Health

[+1]

100 项与 Liposomal NDDP 相关的临床结果

登录后查看更多信息

100 项与 Liposomal NDDP 相关的转化医学

登录后查看更多信息

100 项与 Liposomal NDDP 相关的专利（医药）

登录后查看更多信息

34

项与 Liposomal NDDP 相关的文献（医药）

2019-12-04·Artificial Cells, Nanomedicine, and Biotechnology2区 · 工程技术

Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview

2区 · 工程技术

ReviewOA

作者: Mavlyanova, Rukhshona ; Parveen, Amna ; Farooq, Muhammad Asim ; Haleem Khan, Daulat ; Boakye-Yiadom, Kofi Oti ; Farooq, Anum ; Wang, Bo ; Kesse, Samuel ; Joelle Maviah, Mily Bazezy ; Sied Filli, Mensura ; Aquib, Md

Cisplatin cis-(diammine)dichloridoplatinum(II) (CDDP) is the first platinum-based complex approved by the food and drug administration (FDA) of the United States (US). Cisplatin is the first line chemotherapeutic agent used alone or combined with radiations or other anti-cancer agents for a broad range of cancers such as lung, head and neck. Aroplatin™, Lipoplatin™ and SPI-077 are PEGylated liposome-based nano-formulations that are still under clinical trials. They have many limitations, for example, poor aqueous solubility, drug resistance and toxicities, which can be overcome by encapsulating the cisplatin in Nemours nanocarriers. The extensive literature from different electronic databases covers the different nano-delivery systems that are developed for cisplatin. This review critically emphasizes on the recent advancement, development, innovations and updated literature reported for different carrier systems for CDDP.

2019-09-01·The Israel Medical Association journal : IMAJ4区 · 医学

Comparison of the Functional Outcomes of Lower Limb Amputees with or without End-Stage Renal Disease.

4区 · 医学

Article

作者: Geron, Ronit ; Tsur, Atzmon ; Shakeer, Nael

BACKGROUNDThe potential for full rehabilitation following amputation among end-stage renal disease patients is poor.OBJECTIVESTo evaluate the functional outcomes and survival among amputees treated with hemodialysis at the end of the rehabilitation procedure.METHODSWe recruited 46 patients after lower limb amputation. Of these individuals, 19 (41.3%) were treated with dialysis and 27 (58.7%) were non-dialysis-dependent patients (NDDP). Both groups were divided into three sub-groups according to their independence with regard to activities of daily living (ADL) and their ability to walk with prostheses.RESULTSThe survival of lower limb amputees treated with dialysis was shorter compared to NDDP. Survival after amputation among the NDDP who were fully or partially independent in ADL and with regard to mobility, was longer compared to the non-mobile amputees as with the patients treated with dialysis.CONCLUSIONSSurvival was significantly longer in lower limb amputees NDDP and shorter in patients who did not achieve a certain level of functioning.

2016-01-01·Journal of Pharmaceutical Sciences3区 · 医学

Preparation, Characterization, and Antitumor Activities of Miriplatin-Loaded Liposomes

3区 · 医学

Article

作者: Zhang, Lili ; Xia, Guimin ; Wang, Xiaowei ; Li, Yunfei ; Liu, Shan ; Ma, Jianan

Because of the insolubility of miriplatin in water, miriplatin and lipiodol suspension is the sole formulation of miriplatin approved in Japan to treat hepatocellular carcinoma by transcatheter arterial chemoembolization. Until now, there have been no reports of other pharmaceutical formulations of miriplatin except miriplatin/lipiodol suspension. In this study, we aimed not only to develop miriplatin-loaded liposomes (lipomiriplatins) which could be administrated systematically for tumors besides hepatocellular carcinoma but also to ascertain whether miriplatin, like its analog of NDDP, was a liposome-dependent antitumor agent. We found that miriplatin could be successfully incorporated into liposomes, and both the stability and antitumor activity of lipomiriplatins were independent of the liposomal compositions. Especially, HPLC was successfully established as the quantitative method for lipomiriplatins, which completely eliminated the interference of cholesterol. Lipomiriplatins possessed favorable colloidal properties (99.71 ± 0.56 nm, -50 mV), high drug-loading capacity (about 2.2 mg/mL), excellent entrapment efficiency (>95%), and robust stability. The remarkable antitumor activities of lipomiriplatin were proved to be mediated by inducing cell apoptosis and were comparable to that of the commercial cisplatin and oxaliplatin injections, indicating that lipomiriplatins showed great promise for future potential clinical application via systematic administration.

100 项与 Liposomal NDDP 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
食管癌	临床2期	美国	Aronex Pharmaceuticals, Inc.	2003-04-01
肝细胞癌	临床2期	美国	Aronex Pharmaceuticals, Inc.	2003-04-01
卵巢癌	临床2期	美国	Aronex Pharmaceuticals, Inc.	2003-04-01
胰腺癌	临床2期	美国	Aronex Pharmaceuticals, Inc.	2003-04-01
结直肠癌	临床2期	美国	Agenus, Inc.	-
结直肠癌	临床2期	美国	Agenus, Inc.	-
间皮瘤	临床2期	-	The University of Texas MD Anderson Cancer Center	-
间皮瘤	临床2期	-	Agenus, Inc.	-
肾细胞癌	临床2期	-	Agenus, Inc.	-
肾细胞癌	临床2期	-	The University of Texas MD Anderson Cancer Center	-